Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Texts that could transform trans teen sexual health

NCT ID NCT07681908

Prevention Sponsor: Center for Innovative Public Health Research Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 02, 2026 · Last updated Jul 02, 2026

Summary

This study tests a 5-month text-messaging program called #TranscendentHealth, created specifically for transgender boys and gender-diverse youth assigned female at birth, ages 14 to 18. The program aims to improve condom use, birth control use, and HIV/STI testing by addressing the unique needs and experiences of these teens. Participants are randomly assigned to receive either the tailored program or a general sexual health text program, and complete surveys over about a year.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
#TranscendentHealth text messaging program
What this could lead to
If effective, this could provide a scalable, private way to improve sexual health and reduce unintended pregnancy among transgender and gender-diverse youth.
What could go wrong
This is an early-stage adaptation of an existing program, and its success depends on whether the tailored content engages participants better than a general program. Results may not apply to all youth.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 467 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jun 2026

An estimate. Start dates often move.

Expected to finish

Jun 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

14 to 18 years

Sex

Female participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Assigned female sex at birth * Does not have an exclusively cisgender gender identity (e.g., identifies as transgender boy, nonbinary, gender fluid, or unsure of gender identity) * Age 14 to 18 years and has not yet graduated from high school * Exclusive owner of a cell phone with an unlimited text messaging plan * Has access to the Internet to complete online surveys * Plans to keep the same cell phone number for at least the next 6 months * Able to provide informed assent (ages 14-17) or consent (age 18), including the capacity to do so * Has not participated in a prior #TranscendentHealth study activity and does not know anyone currently enrolled in the study Exclusion Criteria: * Has graduated from high school * Has participated in a prior #TranscendentHealth study activity (focus groups, Content Advisory Teams, or beta test) * Knows another person currently enrolled in the study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV infection are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Sexual Behavior HIV infectious disease prevention target sexually transmitted disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV infection Pregnancy (unwanted) Sexual behavior Sexually transmitted disease (STD)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Center for Innovative Public Health Research (CiPHR)

    San Clemente, California, 92672, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.